Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Feb 18;221(5):681-684.
doi: 10.1093/infdis/jiz067.

Drug Costs: What Can Infectious Diseases Physicians Do?

Shashi N Kapadia  1 , Roy M Gulick  1
Affiliations
Editorial

Drug Costs: What Can Infectious Diseases Physicians Do?

Shashi N Kapadia et al. J Infect Dis. .
No abstract available

Keywords: Harvoni; Sovaldi; cost-benefit analysis; drug cost; generic Drugs; health care costs; health policy; linezolid; medical ethics; pharmacoeconomics; practice guidelines; prescription drugs; truvada.

PubMed Disclaimer

Comment on

References

    1. Costantini S, Walensky RP. The costs of drugs in infectious diseases: branded, generics and why we should care. J Infect Dis 2020; 221:690–6. - PubMed
    1. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 2015; 61:157–68. - PMC - PubMed
    1. Najafzadeh M, Andersson K, Shrank WH, et al. . Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015; 162:407–19. - PubMed
    1. Linas BP, Barter DM, Morgan JR, et al. . The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015; 162:619–29. - PMC - PubMed
    1. Kapadia SN, Jeng PJ, Schackman BR, Bao Y. State Medicaid hepatitis C treatment eligibility criteria and use of direct-acting antivirals. Clin Infect Dis 2018; 66:1618–20. - PMC - PubMed